TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 ...

Tonix Pharmaceuticals Holding Corp TNXP shares are trading lower Monday morning, hitting a fresh 52-week low as investors ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, ...

Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for ...

Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) shares have nearly doubled over the past month despite the pullback on Wednesday. Here’s what you need to know. What To Know: Tonix shares traded higher in ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals Holding Corp.’s (NASDAQ:TNXP) Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults.

Tonix Pharmaceuticals drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due Friday. If ...

Long COVID Afflicts Approximately 19% of Patients Following COVID-19 1, and is Expected to be a Global Health Burden Fibromyalgia-Type Long COVID with Multi-Site Pain Affects Approximately 40% of Long ...

Tonix Pharmaceuticals Holding Corp.'s key value driver is TNX-102 SL for fibromyalgia, with an FDA decision expected in August 2025; approval could spike shares, and rejection could devastate them.